GSK PLC Sponsored ADR $GSK Stock Purchased by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC boosted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 5.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 438,220 shares of the pharmaceutical company’s stock after acquiring an additional 23,934 shares during the period. GSK accounts for 1.0% of Foster Victor Wealth Advisors LLC’s portfolio, making the stock its 24th largest position. Foster Victor Wealth Advisors LLC’s holdings in GSK were worth $21,674,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kahn Brothers Group Inc. bought a new position in shares of GSK in the 2nd quarter worth $8,305,000. Nvest Financial LLC acquired a new stake in shares of GSK during the second quarter worth $2,236,000. Keystone Financial Planning Inc. grew its stake in shares of GSK by 3,114.8% during the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares during the period. Baird Financial Group Inc. grew its stake in shares of GSK by 110.3% during the second quarter. Baird Financial Group Inc. now owns 50,129 shares of the pharmaceutical company’s stock worth $2,628,000 after purchasing an additional 26,290 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in GSK by 842.9% in the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after purchasing an additional 852,437 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 1.1%

Shares of NYSE GSK opened at $50.09 on Thursday. The company’s fifty day moving average is $49.55 and its 200-day moving average is $51.49. The stock has a market cap of $101.31 billion, a price-to-earnings ratio of 10.64, a P/E/G ratio of 2.28 and a beta of 0.33. GSK PLC Sponsored ADR has a twelve month low of $42.85 and a twelve month high of $61.69. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. During the same quarter in the previous year, the business earned $0.47 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts predict that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 annualized dividend and a yield of 3.6%. The ex-dividend date was Friday, August 14th. GSK’s dividend payout ratio is presently 55.31%.

Analyst Ratings Changes

GSK has been the topic of several analyst reports. HSBC reissued a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research report on Monday, September 28th. The Goldman Sachs Group restated a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Citigroup initiated coverage on GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. reiterated a “sell” rating on shares of GSK in a research report on Thursday, October 1st. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $55.33.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Hibsago for adults with chronic hepatitis B without cirrhosis. The treatment is described as the first potential “functional cure,” offering some patients the possibility of stopping long-term therapy and creating a significant new commercial opportunity. US FDA approves GSK’s hepatitis B drug
• Positive Sentiment: Jefferies reiterated its Buy rating and 2,500p price target, citing the Hibsago approval and maintaining a potential annual sales forecast of approximately £2.2 billion. This supports the view that the drug could become an important long-term growth driver. GSK hepatitis B drug approval supports £2.2bn sales forecast
• Positive Sentiment: GSK’s Jemperli received U.S. approvals, including accelerated approval for advanced rectal cancer and recognition as the first approved immunotherapy for certain locally advanced kidney cancers. The expanded indications could broaden Jemperli’s revenue base. GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
• Positive Sentiment: GSK completed its exclusive licensing agreement with HUTCHMED for a KRAS-EGFR antibody-drug conjugate outside China and also announced a strategic partnership involving Mubadala Bio’s IDS, supporting efforts to expand its oncology pipeline and external innovation. HUTCHMED Announces Closing of KRAS-EGFR License to GSK
• Neutral Sentiment: Analysts expect GSK to report quarterly earnings shortly. One preview warns of a possible year-over-year earnings decline and suggests the company may lack the typical factors associated with a likely earnings beat, creating a near-term event risk. Analysts Estimate GSK to Report a Decline in Earnings
• Negative Sentiment: CSL selected GSK executive Deborah Waterhouse as its next CEO. Her departure may raise concerns about management continuity, although it does not change GSK’s operating outlook directly. CSL taps GSK’s Deborah Waterhouse as CEO

GSK Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.